This is an international site for FEMARA® (letrozole) and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country.
FEMARA® (letrozole) is indicated for adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.
FEMARA® (letrozole) is also indicated for:
Extended adjuvant treatment of hormone-dependent early breast cancer in postmenopausal women who have received prior standard adjuvant tamoxifen therapy for 5 years.
First-line treatment in postmenopausal women with hormone-dependent advanced breast cancer.
Advanced breast cancer in women with natural or artificially induced postmenopausal status after relapse or disease progression, who have previously been treated with anti-estrogens.
Click here for Important Safety Information for FEMARA ®.
*Distant disease-free survival is a secondary end point of BIG 1-98; the primary end point of the study is disease-free survival. Approval is based on a median 26-month follow-up.1
References: 1. FEMARA® (letrozole) [summary of product characteristics]. Basel, Switzerland: Novartis Pharma AG; 2010. 2. Gradishar W. Landmark trials in endocrine adjuvant therapy for breast carcinoma. Cancer. 2006;106(5):975-981.